Ligand Pharmaceuticals swings to Q3 net loss of $28.49 million from year-earlier profit
Bitget2026/10/29 11:18- Ligand Pharmaceuticals’ third-quarter 2026 adjusted earnings per diluted share fell 14% year-over-year to $2.67.
- Adjusted total revenues and income rose 26% year-over-year to $78.7 million, excluding prior-year Pelthos-related income.
- The completed XOMA Royalty acquisition more than doubled the portfolio to over 200 assets.
- Full-year 2026 adjusted earnings guidance increased to $9.50–$9.75 per diluted share from $9–$9.50.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Is AI an engine or a killer? Morgan Stanley provides answers with data: productivity soars, but nearly 90% of the benefits are taken by 12 industries
Morgan Stanley stated that the productivity dividends from AI are concentrated in 12 highly exposed industries, with growth rates reaching twice the twenty-year average. For the first time, signs of job replacement have emerged.
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
Crypto prices
More
